

February 2, 2023

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Toshiya Sasai
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554

Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year

Chugai Pharmaceutical Co., Ltd. hereby announces that there is a difference regarding the individual financial results (Japanese standard) for the year ended December 2022 (Jan. 1, 2022 – Dec. 31, 2022) as compared to the actual results for the previous year (Jan. 1, 2021 – Dec. 31, 2021).

1. Difference between the actual results for the year ended December 2022 and the actual results for the previous year

	Revenues	Operating Income	Ordinary Income	Net Income	Earnings per Share
Actual results for the previous year (A) (Jan. 1, 2021 – Dec. 31, 2021)	(millions of yen) 993,350	(millions of yen) 410,313	(millions of yen) 414,116	(millions of yen) 294,713	(Yen Sen) 179.25
Actual results for this year (B) (Jan. 1, 2022 – Dec. 31, 2022)	(millions of yen) 1,250,901	(millions of yen) 517,816	(millions of yen) 525,010	(millions of yen) 366,728	(Yen Sen) 222.96
Change (B-A)	(millions of yen) 257,551	(millions of yen) 107,503	(millions of yen) 110,894	(millions of yen) 72,015	-
Change (%)	25.9	26.2	26.8	24.4	-

2. Reasons for the difference occurring

The difference occurred mainly due to the strong performance of new products and mainstay products in the domestic market, increases in exports to Roche, as well as income related to the settlement agreement with Alexion Pharmaceuticals, Inc.

###